This article was originally published in The Tan Sheet
Antiperspirants among products company will consider developing in the future, CEO Herb Baum states during Prudential Securities Consumer Conference in Boston Sept. 3. Products would need to reflect a "meaningful point of difference" compared with competitors, however. "I don't want to throw some antiperspirants...at the market that are the same as the stuff that's out there, because we'll get killed," Baum stressed. Firm is aiming to redefine its $20 bil. personal care business by dividing marketing and product development focus in Coast, Tone, Dial and Pure & Natural brands to address young men's grooming, beauty, skin protection and hypo-allergenic categories, respectively...
You may also be interested in...
Amneal is close to a filed pipeline of three biosimilar products in the US, while furthering ambitions in the complex generics and 505(b)(2) space, management told the virtual J.P. Morgan Healthcare Conference.
Zydus Cadila is to begin testing a three-dose recombinant DNA vaccine candidate in Phase III Indian trials, which might enter late-stage development ahead of Inovio and AnGes. The company promised to provide 100-150 million doses by end of 2021 at the J.P. Morgan Conference, though adherence could be a roadblock.
Sun Pharma’s founder and MD shares with Scrip his views on some key big picture issues, including leveraging pandemic-related regulatory experience for urgently needed products, expectations in the US market, the outlook for M&A, and the potential of e-pharmacies in India.